EWING, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating progress and financial results for the fourth quarter and full year ended December 31, 2016. The Company reported revenue of $14.2 million for the fourth quarter of 2016 and $52.2 million for the full year ended December 31, 2016. Net loss per share was $0.03 and $0.16 for the fourth quarter and full year 2016, respectively.
“I am pleased to announce another year of continued strong financial results for the Company and significant progress with a number of our pipeline initiatives which include both internally developed products as well as partnered programs utilizing our device technology,” said Robert F. Apple, President and Chief Executive Officer of the Company. “Record full year 2016 revenue is the result of the launch of Sumatriptan Injection USP, continued growth of OTREXUP and significant development revenue generated from our alliance business. In addition, the filing of a New Drug Application for QST with an October 2017 action date was the highlight of our successes in the past year. We look forward to 2017 and beyond as we anticipate the potential for a number of internal and partnered combination drug-device product approvals over the coming years.”
“I am pleased to announce another year of continued strong financial results for the Company and significant progress with a number of our pipeline initiatives which include both internally developed products as well as partnered programs utilizing our device technology,” said Robert F. Apple, President and Chief Executive Officer of the Company. “Record full year 2016 revenue is the result of the launch of Sumatriptan Injection USP, continued growth of OTREXUP and significant development revenue generated from our alliance business. In addition, the filing of a New Drug Application for QST with an October 2017 action date was the highlight of our successes in the past year. We look forward to 2017 and beyond as we anticipate the potential for a number of internal and partnered combination drug-device product approvals over the coming years.”
